{"id":6013,"date":"2024-09-02T12:55:55","date_gmt":"2024-09-02T10:55:55","guid":{"rendered":"https:\/\/thoraxzentrum-ruhrgebiet.de\/vita-pd-dr-med-daniel-c-christoph\/"},"modified":"2026-10-23T08:53:41","modified_gmt":"2026-10-23T06:53:41","slug":"vita-pd-dr-med-daniel-c-christoph","status":"publish","type":"page","link":"https:\/\/thoraxzentrum-ruhrgebiet.de\/tr\/vita-pd-dr-med-daniel-c-christoph\/","title":{"rendered":"Vita PD Dr. med. Daniel C. Christoph"},"content":{"rendered":"\n<style type=\"text\/css\" data-created_by=\"avia_inline_auto\" id=\"style-css-av-2ulvfw-b4a928547b9b45cbce6996d26cccfffe\">\n#top .av-special-heading.av-2ulvfw-b4a928547b9b45cbce6996d26cccfffe{\npadding-bottom:10px;\n}\nbody .av-special-heading.av-2ulvfw-b4a928547b9b45cbce6996d26cccfffe .av-special-heading-tag .heading-char{\nfont-size:25px;\n}\n.av-special-heading.av-2ulvfw-b4a928547b9b45cbce6996d26cccfffe .av-subheading{\nfont-size:15px;\n}\n<\/style>\n<div  class='av-special-heading av-2ulvfw-b4a928547b9b45cbce6996d26cccfffe av-special-heading-h1  avia-builder-el-0  el_before_av_image  avia-builder-el-first '><h1 class='av-special-heading-tag '  itemprop=\"headline\"  >Vita PD Dr. med. Daniel C. Christoph <\/h1><div class=\"special-heading-border\"><div class=\"special-heading-inner-border\"><\/div><\/div><\/div>\n\n\n<style type=\"text\/css\" data-created_by=\"avia_inline_auto\" id=\"style-css-av-3sm5ik-1fcf19d18429e052d7dd412783c170d4\">\n#top .hr.hr-invisible.av-3sm5ik-1fcf19d18429e052d7dd412783c170d4{\nheight:30px;\n}\n<\/style>\n<div  class='hr av-3sm5ik-1fcf19d18429e052d7dd412783c170d4 hr-invisible  avia-builder-el-2  el_after_av_image  el_before_av_textblock '><span class='hr-inner '><span class=\"hr-inner-style\"><\/span><\/span><\/div>\n<section  class='av_textblock_section av-1ul5cc-f6b4a3eef008426895aebce41a3aabc5 '   itemscope=\"itemscope\" itemtype=\"https:\/\/schema.org\/CreativeWork\" ><div class='avia_textblock'  itemprop=\"text\" ><h2><strong>\u00d6zge\u00e7mi\u015f<\/strong><\/h2>\n<p><strong>1999 \u2013 2002: <\/strong>Ruhr-Universit\u00e4t Bochum\u2019da t\u0131p e\u011fitimi<\/p>\n<p><strong>2002 &#8211; 2005: <\/strong>Universit\u00e4t Duisburg-Essen\u2019de t\u0131p e\u011fitimi<\/p>\n<p><strong>2005 &#8211; 2006: <\/strong>Ruhr-Universit\u00e4t Bochum\u2019da t\u0131p e\u011fitimi<\/p>\n<p><strong> 2006 &#8211; 2015: <\/strong>Dahiliye Merkezi b\u00fcnyesindeki Anjiyoloji, Endokrinoloji, Gastroenteroloji ve Hepatoloji, Kardiyoloji ve Nefroloji kliniklerinde; ayr\u0131ca Dahiliye Klini\u011fi (T\u00fcm\u00f6r Ara\u015ft\u0131rmalar\u0131) ile Konservatif Onkoloji Merkezi b\u00fcnyesindeki Hematoloji ve Kemik \u0130li\u011fi Transplantasyonu kliniklerinde bilimsel \u00e7al\u0131\u015fan ve asistan hekim<\/p>\n<p><strong>2016 &#8211; 2017: <\/strong>Dahiliye Klini\u011fi (T\u00fcm\u00f6r Ara\u015ft\u0131rmalar\u0131), Universit\u00e4tsklinkum Essen\u2019de bilimsel \u00e7al\u0131\u015fan (Oberarzt) ve bir \u00e7al\u0131\u015fma grubunun (toraks onkolojisi ara\u015ft\u0131rma laboratuvar\u0131) lideri<\/p>\n<p><strong>2017 &#8211; 2021: <\/strong>Evangelische Huyssensstiftung, Evangelische Kliniken Essen-Mitte, Dahili Onkoloji ve Onkolojik Palyatif T\u0131p Klini\u011fi\u2019nde Oberarzt<\/p>\n<p><strong>2021 <\/strong><strong>&#8211; 2024: <\/strong>Evangelische Huyssensstiftung, Evangelische Kliniken Essen-Mitte, Dahili Onkoloji ve Onkolojik Palyatif T\u0131p Klini\u011fi\u2019nde Ba\u015fhekim Yard\u0131mc\u0131s\u0131 (Leitender Oberarzt)<\/p>\n<p><strong>2018 &#8211; 2022: <\/strong>Medizinisches Versorgungszentrum H\u00e4matologie und Onkologie Essen gGmbH\u2019de kadrolu uzman hekim<\/p>\n<p><strong>2024 &#8211; bug\u00fcn: <\/strong>Evang. Krankenhaus Herne-Eickel, Pn\u00f6moloji ve Enfeksiyoloji Klini\u011fi, Torasik Onkoloji Seksiyonu Ba\u015fkan\u0131<\/p>\n<h2>Tan\u0131n\u0131rl\u0131k, burslar ve \u00f6d\u00fcller<\/h2>\n<p><strong>2010 \u2013 2012:<\/strong> \u201c<em>International Association for the Study of Lung Cancer (IASLC) Fellowship Award<\/em>\u201d<\/p>\n<p><strong>2011:<\/strong> \u201c<em>American Society of Clinical Oncology (ASCO) Foundation Merit Award<\/em>\u201d<\/p>\n<p><strong><b>2015: <\/b><\/strong>Hematoloji \/ Onkoloji yan dal unvan\u0131yla Dahiliye Uzman\u0131 olarak tan\u0131nma<\/p>\n<h2>Bilimsel meslek derneklerine \u00fcyelik<\/h2>\n<p>ASCO (<em>American Society of Clinical Oncology<\/em>)<\/p>\n<p>DGHO (Deutsche Gesellschaft f\u00fcr H\u00e4matologie und Onkologie)<\/p>\n<p>ESMO (<em>European Society of Medical Oncology<\/em>)<\/p>\n<p>IASLC (<em>International Association for the Study of Lung Cancer<\/em>)<\/p>\n<h2>Klinik \u00e7al\u0131\u015fmalarda ara\u015ft\u0131rmac\u0131 hekim g\u00f6revleri (sorumlu ba\u015f ara\u015ft\u0131rmac\u0131)<\/h2>\n<p><strong>BI1199.93<\/strong>:<em> \u201eRezeksiyon yap\u0131lamayan malign plevral mezotelyoma hastalar\u0131n\u0131n tedavisi i\u00e7in, pemetreksed\/sisplatin ile kombinasyon halinde nintedanib uygulanmas\u0131n\u0131 takiben nintedanib monoterapisinin s\u00fcrd\u00fcr\u00fclmesinin; pemetreksed\/sisplatin ile kombinasyon halinde plasebo uygulanmas\u0131n\u0131 takiben plasebo monoterapisinin s\u00fcrd\u00fcr\u00fclmesine kar\u015f\u0131la\u015ft\u0131r\u0131ld\u0131\u011f\u0131, \u00e7ift k\u00f6r, randomize, \u00e7ok merkezli, Faz II \u00e7al\u0131\u015fma\u201d<\/em><\/p>\n<p><strong>MORAb-009-201<\/strong>: <em>\u201eRezeksiyon yap\u0131lamayan malign plevral mezotelyomal\u0131 olgularda, pemetreksed ve sisplatin ile kombinasyon halinde amatuksimab\u0131n g\u00fcvenlilik ve etkinli\u011finin de\u011ferlendirildi\u011fi randomize, \u00e7ift k\u00f6r, plasebo kontroll\u00fc \u00e7al\u0131\u015fma\u201d<\/em><\/p>\n<p><strong><em>BAY 94-9343 \/ 15743: <\/em><\/strong><em>\u201eBirinci basamak platin\/pemetreksed temelli kemoterapi sonras\u0131 progresyon g\u00f6steren, mezotelin a\u015f\u0131r\u0131 ekspresyonu olan ileri veya metastatik malign plevral mezotelyoma hastalar\u0131nda, intraven\u00f6z anetumab ravtansine (BAY 94-9343) veya vinorelbinin de\u011ferlendirildi\u011fi randomize, a\u00e7\u0131k etiketli, aktif kontroll\u00fc Faz II \u00e7al\u0131\u015fma\u201d<\/em><\/p>\n<p><strong><em>CheckMate743:<\/em><\/strong><em> Rezeksiyon yap\u0131lamayan plevral mezotelyoma hastalar\u0131nda birinci basamak tedavi olarak nivolumab + ipilimumab\u0131n; pemetreksed ve sisplatin veya karboplatin ile kar\u015f\u0131la\u015ft\u0131r\u0131ld\u0131\u011f\u0131 \u00e7al\u0131\u015fma<\/em><\/p>\n<p><strong><em>Roche Immotion WO29637<\/em><\/strong><em>: \u201eTedavi edilmemi\u015f ileri evre renal h\u00fccreli karsinom hastalar\u0131nda, atezolizumab\u0131n (anti-PD-L1 antikoru) bevacizumab ile kombinasyonunun; sunitinib ile kar\u015f\u0131la\u015ft\u0131r\u0131ld\u0131\u011f\u0131 Faz III, a\u00e7\u0131k etiketli, randomize \u00e7al\u0131\u015fma\u201c<\/em><\/p>\n<p><strong><em>CheckMate 592:<\/em><\/strong><em> \u201cTedavi almam\u0131\u015f Evre IV veya n\u00fcks etmi\u015f k\u00fc\u00e7\u00fck h\u00fccreli d\u0131\u015f\u0131 akci\u011fer kanseri (NSCLC) hastalar\u0131nda nivolumab\u0131n ipilimumab ile kombinasyonunun etkilerinin ara\u015ft\u0131r\u0131ld\u0131\u011f\u0131 ke\u015fifsel \u00e7al\u0131\u015fma\u201d <\/em> <\/p>\n<p><strong><em>AIO-YMO\/TRK-0416: \u201c<\/em><\/strong><em>K\u0131r\u0131lgan ve ya\u015fl\u0131 metastatik NSCLC hastalar\u0131nda durvalumab (MEDI4736)\u201d<\/em><\/p>\n<p><strong><em>KEYLYNK-006:<\/em><\/strong><em> \u201e<\/em><em>Metastatik skuam\u00f6z olmayan k\u00fc\u00e7\u00fck h\u00fccreli d\u0131\u015f\u0131 akci\u011fer kanseri olan kat\u0131l\u0131mc\u0131larda birinci basamak tedavide, pemetreksed\/platin (karboplatin veya sisplatin) ile kombinasyon halinde pembrolizumab\u0131 takiben pembrolizumab ve idame olaparibin; birinci basamakta idame pemetreksed ile kar\u015f\u0131la\u015ft\u0131r\u0131ld\u0131\u011f\u0131 Faz 3 \u00e7al\u0131\u015fma\u201d<\/em><\/p>\n<p><strong><em>KEYLYNK-008:<\/em><\/strong><em> \u201e<\/em><em>Metastatik skuam\u00f6z k\u00fc\u00e7\u00fck h\u00fccreli d\u0131\u015f\u0131 akci\u011fer kanserinin (NSCLC) birinci basamak tedavisinde, karboplatin\/taksan (paklitaksel veya nab-paklitaksel) ile kombinasyon halinde pembrolizumab\u0131 takiben, idame olaparib ile veya olmaks\u0131z\u0131n pembrolizumab\u0131n de\u011ferlendirildi\u011fi Faz 3 \u00e7al\u0131\u015fma\u201d<\/em><\/p>\n<p><strong><em>NICITA:<\/em><\/strong><em> \u201cCerrahi sonras\u0131 plevral mezotelyomada kemoterapi ile nivolumab\u201d<\/em><\/p>\n<p><strong><em>CONTACT-01 (GO41892):<\/em><\/strong><em> Daha \u00f6nce anti-PD-L1\/PD-1 antikoru ve platin i\u00e7eren kemoterapi ile tedavi edilmi\u015f metastatik k\u00fc\u00e7\u00fck h\u00fccreli d\u0131\u015f\u0131 akci\u011fer kanseri hastalar\u0131nda, kabozantinib ile kombinasyon halinde atezolizumab\u0131n; dosetaksel monoterapisine kar\u015f\u0131 etkinlik, g\u00fcvenlilik ve farmakokineti\u011finin de\u011ferlendirildi\u011fi Faz III, \u00e7ok merkezli, randomize, a\u00e7\u0131k etiketli, kontroll\u00fc \u00e7al\u0131\u015fma.<\/em><\/p>\n<p><strong><em>MK3475-789: <\/em><\/strong><em>Metastatik skuam\u00f6z olmayan k\u00fc\u00e7\u00fck h\u00fccreli d\u0131\u015f\u0131 akci\u011fer kanseri (NSCLC) olan, TKI\u2019ye diren\u00e7li EGFR mutasyonlu t\u00fcm\u00f6rl\u00fc kat\u0131l\u0131mc\u0131larda, pemetreksed + platin kemoterapisinin pembrolizumab (MK-3475) ile veya olmaks\u0131z\u0131n kar\u015f\u0131la\u015ft\u0131r\u0131ld\u0131\u011f\u0131 randomize, \u00e7ift k\u00f6r, Faz 3 \u00e7al\u0131\u015fma.<\/em><\/p>\n<p><strong><em>CheckMate 73L (CA209-73L):<\/em><\/strong><em> Daha \u00f6nce tedavi edilmemi\u015f, lokal ileri evre k\u00fc\u00e7\u00fck h\u00fccreli d\u0131\u015f\u0131 akci\u011fer kanserinde; e\u015fzamanl\u0131 kemoradyoterapi (CCRT) ile birlikte nivolumab\u0131 takiben nivolumab + ipilimumab\u0131n veya CCRT ile birlikte nivolumab\u0131 takiben nivolumab\u0131n; CCRT\u2019yi takiben durvalumab ile kar\u015f\u0131la\u015ft\u0131r\u0131ld\u0131\u011f\u0131 Faz 3, randomize, a\u00e7\u0131k etiketli \u00e7al\u0131\u015fma<\/em><\/p>\n<p><strong><em>DOLPHIN:<\/em><\/strong><em> S\u0131n\u0131rl\u0131 hastal\u0131k evresindeki k\u00fc\u00e7\u00fck h\u00fccreli akci\u011fer kanseri hastalar\u0131nda, sisplatin\/etoposid ve e\u015fzamanl\u0131 radyoterapinin durvalumab ile kombinasyonu ve ard\u0131ndan durvalumab ile idame tedavisinin; sisplatin\/etoposid ve e\u015fzamanl\u0131 radyoterapi ile kar\u015f\u0131la\u015ft\u0131r\u0131ld\u0131\u011f\u0131 Faz II randomize \u00e7al\u0131\u015fma.<\/em><\/p>\n<p><strong><em>SAPPHIRE\/MIRATI 516-005:<\/em><\/strong><em> \u201cKontrol noktas\u0131 inhibit\u00f6r\u00fc tedavisi ile kombinasyon halinde platin bazl\u0131 kemoterapi s\u0131ras\u0131nda veya sonras\u0131nda hastal\u0131\u011f\u0131 progresyon g\u00f6steren ileri evre skuam\u00f6z olmayan k\u00fc\u00e7\u00fck h\u00fccreli d\u0131\u015f\u0131 akci\u011fer kanseri hastalar\u0131nda, nivolumab ile kombinasyon halinde sitravatinibin; dosetaksel ile kar\u015f\u0131la\u015ft\u0131r\u0131ld\u0131\u011f\u0131 randomize Faz 3 \u00e7al\u0131\u015fma\u201d<\/em><\/p>\n<p><strong><em>MIRATI 849-012:<\/em><\/strong><em> \u201cDaha \u00f6nce tedavi edilmi\u015f, KRAS G12C mutasyonlu k\u00fc\u00e7\u00fck h\u00fccreli d\u0131\u015f\u0131 akci\u011fer kanseri hastalar\u0131nda MRTX849\u2019un dosetaksel ile kar\u015f\u0131la\u015ft\u0131r\u0131ld\u0131\u011f\u0131 randomize Faz 3 \u00e7al\u0131\u015fma\u201d<\/em><\/p>\n<p><strong><em>MyRisk\/IBA1160:<\/em><\/strong><em> \u201cBir \u00f6ng\u00f6r\u00fc arac\u0131na dayanarak CINV geli\u015fme riski y\u00fcksek olan ve MEC alan hastalarda oral Akynzeo\u00ae\u2019nun etkinlik ve g\u00fcvenlili\u011finin de\u011ferlendirilmesi. \u00c7ok uluslu ve \u00e7ok merkezli bir \u00e7al\u0131\u015fma\u201d<\/em><\/p>\n<p><strong><em>CA224104\/RELATIVITY-104:<\/em><\/strong><em> \u201cEvre IV veya n\u00fcks etmi\u015f k\u00fc\u00e7\u00fck h\u00fccreli d\u0131\u015f\u0131 akci\u011fer kanseri (NSCLC) olan kat\u0131l\u0131mc\u0131larda birinci basamak tedavi olarak, kemoterapi ile kombinasyon halinde relatlimab + nivolumab\u0131n; kemoterapi ile kombinasyon halinde nivolumab ile kar\u015f\u0131la\u015ft\u0131r\u0131ld\u0131\u011f\u0131 Faz 2 randomize, \u00e7ift k\u00f6r \u00e7al\u0131\u015fma\u201d<\/em><\/p>\n<p><strong><em>IMforte\/GO43104:<\/em><\/strong><em> \u201cYayg\u0131n evre k\u00fc\u00e7\u00fck h\u00fccreli akci\u011fer kanseri (ES-SCLC) olan kat\u0131l\u0131mc\u0131larda, birinci basamak<\/em><\/p>\n<p><em>Karboplatin, etoposid ve atezolizumab ile ind\u00fcksiyon tedavisini takiben, idame tedavisi olarak atezolizumab ile kar\u015f\u0131la\u015ft\u0131rmal\u0131 \u015fekilde atezolizumab ile kombinasyon halinde lurbinektedinin de\u011ferlendirildi\u011fi Faz III, randomize, a\u00e7\u0131k etiketli, \u00e7ok merkezli \u00e7al\u0131\u015fma\u201d<\/em><\/p>\n<p><strong><em>ANTELOPE:<\/em><\/strong><em> \u201cMetastatik TTF-1 negatif akci\u011fer adenokarsinomunda atezolizumab\/karboplatin\/nab-paklitaksel ile pembrolizumab\/platin\/pemetreksed kar\u015f\u0131la\u015ft\u0131rmas\u0131<\/em><\/p>\n<\/div><\/section>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":4,"featured_media":0,"parent":0,"menu_order":274,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-6013","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/thoraxzentrum-ruhrgebiet.de\/tr\/wp-json\/wp\/v2\/pages\/6013","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thoraxzentrum-ruhrgebiet.de\/tr\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/thoraxzentrum-ruhrgebiet.de\/tr\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/thoraxzentrum-ruhrgebiet.de\/tr\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/thoraxzentrum-ruhrgebiet.de\/tr\/wp-json\/wp\/v2\/comments?post=6013"}],"version-history":[{"count":3,"href":"https:\/\/thoraxzentrum-ruhrgebiet.de\/tr\/wp-json\/wp\/v2\/pages\/6013\/revisions"}],"predecessor-version":[{"id":6016,"href":"https:\/\/thoraxzentrum-ruhrgebiet.de\/tr\/wp-json\/wp\/v2\/pages\/6013\/revisions\/6016"}],"wp:attachment":[{"href":"https:\/\/thoraxzentrum-ruhrgebiet.de\/tr\/wp-json\/wp\/v2\/media?parent=6013"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}